Seattle Genetics has big plans for 2017

News on 18 Dec , 2016
Share on FacebookShare on Google+Share on LinkedInTweet about this on Twitter

As Bothell’s Seattle Genetics surpasses 900 employees and continues its growth, the local biotechnology firm looks to add as many as 200 employees next year. Seattle Genetics is most known for its drug Adcetris, which treats Hodgkin Lymphoma, a cancer of the lymphatic system, which is part of the immune system.

The biotech firm has already hit $400 million in revenue for 2016 and suggest that they look to more than double their sales and revenue for 2017.

To read more on the latest from Seattle Genetics, read the Seattle Times article here.